Search
Featured Client List
|
Applied Biosensors |
|
|
Fluidx Medical Technology |
|
|
Kuda |
|
|
Purgo Scientific |
|
|
TheraTarget |
|
|
VicoLine Medical |
Applied Biosensors
Applied Biosensors LLC (AB) was established in 2014 to transform the production of life-saving medicines. The company has developed a biosensors and analytics platform for continuous real-time monitoring of a wide range of biochemicals, applicable to multiple markets. The company’s first product, InSens4™, is an in-line multi-analyte sensor that can simultaneously monitor critical process parameters such as Glucose, Lactate, Osmolality, and pH. The InSens4™ is designed for use in the biomanufacturing industry. The patent-protected base technology is expandable to other analytes, including large molecules (i.e., proteins). Applied Biosensors plans to offer data analytics services based on the data generated by its sensors with a long-term vision to bringing machine learning and artificial intelligence to bioproduction, thus enabling complete automation of bioproduction facilities.
Key Patents
US10448895B2, Sensor Systems
US20160215253A1, Multi-analyte sensing using hydrogels and magnetometers
US20190231218A1, Hydrogel sensor assembly
BiG Accolades (GLOBAL CHANGE)
NSF: SBIR Phase II: In-line sensor for monitoring monoclonal antibody production based on hydrogels containing peptide aptamers.
NIIMBL: Multi-Analyte In-line Sensor for Biomanufacturing Applications Based on Analyte-Responsive Smart Hydrogels.
ARMI: Multi-Analyte, Non-Invasive Sensor for Cell Biomanufacturing
Contact Information
Prashant Tathireddy
p.tathireddy@appliedbiosensors.com
Fluidx Medical Technology
Fluidx Medical Technology is a Salt Lake City, Utah based company focused on developing the GPX Embolic Device and other innovative medical technologies. The GPX Embolic Device is a novel embolic agent that requires minimal preparation and is designed for ease of use and improved control during material delivery leading to highly targeted, durable vessel occlusions. Fluidx Medical has a seasoned leadership team and clinical advisory group that includes serial med-tech entrepreneurs, proven industry leaders, and thought-leading interventional physicians.
“Best of GEST” selection. Holden, Andrew. “Experience from the GPX Embolic Device First In Human Trial: Renal Tumor Embolizations.” Global Embolization Oncology Symposium Technologies (GEST) Conference, July 2021.
Awards & Publications
Holden, Andrew. “Renal AML with a New Liquid.” Global Embolization Oncology Symposium Technologies (GEST) Conference, April 2021.
Fries, Frederik, et al. “Treatment of experimental aneurysms with a GPX embolic agent prototype: preliminary angiographic and histological results.” J NeuroIntervent Surg. May 2021; pg.1–5
Oliver, Jeremie. “New Polymer Therapy Blocks Blood Flow to Tumors.” Utah Business. April 2021.
2021 BioUtah Entrepreneur & Investor Life Sciences Summit Pitch Competition Finalist.
Second Runner Up for Cardiovascular Research Technologies (CRT) Cardiovascular Innovations Award 2020.
Jones, Joshua et al. “Water-Borne Endovascular Embolics Inspired by the Undersea Adhesive of Marine Sandcastle Worms.” Advanced Healthcare Materials. 2016, 5, pg. 795-801.
Contact Information
Libble Ginster
libble.ginster@fluidxmedical.com
Kuda
Kuda is developing small-molecule inhibitors of HIF-2α, a validated driver of kidney cancer progression. These molecules also induce iron dependent cell death (ferroptosis). This dual action of HIF-2α inhibition combined with increased ferroptotic death will selectively kill kidney cancer cells providing patients with a more effective treatment option.
Contact Information
Mei Koh
mei.koh@kudatherapeutics.com
Purgo Scientific
Purgo Scientific is a medical device company developing a novel method for targeted therapeutic drug delivery. While there are many applications for this method, the initial goal is to treat and prevent biofilm-related surgical site infections that compromise indwelling devices such as orthopedic implants. Targeted drug delivery against biofilms with local, high dose concentrations of antibiotic have a better chance at treating these infections than other therapies. In the United States alone, each year this problem affects as many as 300,000 people and costs the healthcare system up to $10 billion. The ultimate goal for our device is to extend its application beyond the eradication of biofilm-caused infections, and to treat any health issue that benefits from precise medicine delivery, including pain and oncology applications.
Contact Information
Jefferey Siversten
jeff@purgoscientific.com
Thera Target
At TheraTarget, our mission is to challenge the current barriers in cancer therapeutics and drug delivery by treating cancer with greater efficacy. We are developing a targeted drug delivery technology that could drastically improve the efficacy of chemotherapy by allowing the anticancer drugs to be delivered directly to the tumor site. We are also developing a unique embolic technology.
Contact Information
Jeff Harps
jharps@theratarget.com
VicoLine Medical
VicoLine Medical is dedicated to developing cutting-edge, innovative, non-invasive optical imaging techniques for cell-based drug screening assay. Our enabling platform technology provides robust, cost-effective, reliable solutions that overcome the challenges from traditional assays, which significantly improve the efficiency on new drug discovery. We are specialized in customizing biologically inspired bio-probes that achieve high sensitivity and specificity for the detection, visualization, tracking of cell receptor-ligand interaction. We are committed to expanding the new applications of our technology in cell biomarker detection for various human diseases.
Contact Information
Anhong Zhou
azhou@vicolinemedical.com